Medical condition
Drugs
Drugs is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- apremilast (OTEZLA) Antineoplastic and immunomodulating agents (L04)
- upadacitinib (RINVOQ) Antineoplastic and immunomodulating agents (L04)
- tofacitinib (XELJANZ) Antineoplastic and immunomodulating agents (L04)
- etanercept (BRENZYS) Antineoplastic and immunomodulating agents (L04)
- anakinra (KINERET) Antineoplastic and immunomodulating agents (L04)
- ixekizumab (TALTZ) Antineoplastic and immunomodulating agents (L04)
- golimumab (SIMPONI) Antineoplastic and immunomodulating agents (L04)
- baricitinib (OLUMIANT) Antineoplastic and immunomodulating agents (L04)
- abatacept (ORENCIA) Antineoplastic and immunomodulating agents (L04)
- canakinumab (CANAKINUMAB NOVARTIS) Antineoplastic and immunomodulating agents (L04)
- methotrexate (ARX-METHOTREXATE) Antineoplastic and immunomodulating agents (L04)
- obiltoxaximab (NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)) Antiinfectives for systemic use (J06)
Latest Drugs news
Explaining Unapproved Drugs to Payors: FDA Guidance Helps Pharma Avoid Pitfalls
The FDA has issued new guidance on how drug manufacturers can communicate information about unapproved drugs to payors, aiming to reduce legal risks. This article explains the key provisions, including what can and cannot be said about study results, and offers strategic insights for pharma teams.
FDA Oncology Draft Guidance: Reducing Animal Testing for Cancer Drugs
The FDA has issued draft guidance aimed at reducing unnecessary animal testing in oncology drug development. This initiative supports expedited pathways for novel treatments while aligning with the agency's commitment to animal welfare.
2026 Orphan Drugs Report: Navigating Challenges Ahead
The 2026 Orphan Drugs Report highlights critical trends and challenges in the orphan drug landscape, offering insights for pharmaceutical stakeholders.
14 New Weight Loss Drugs: Regulatory Updates and Implications
This article tracks the latest regulatory updates on 14 new weight loss drugs, focusing on implications for pharmaceutical teams and investors. Key insights on FDA processes included.
FDA Restricts Large-Scale Compounding of Weight Loss Drugs
On May 4, 2026, the FDA announced restrictions on large-scale compounding of three weight loss drugs, signaling significant changes in the pharmaceutical landscape. This move has implications for investors and pharmaceutical teams alike.
FDA Guidelines Enhance Generic Bioequivalence in Oncology Drugs
The FDA has released product-specific guidelines that enhance the evaluation of generic bioequivalence in key oncology drugs. This development has significant implications for pharmaceutical companies and investors.
FDA Approves 17 Drugs with Continuous Manufacturing: Implications for Pharma
The FDA has approved 17 drugs using continuous manufacturing, signaling a shift in production technology. This growth in emerging tech has significant implications for the pharmaceutical industry.
FDA Fast Track Designation for Oncology Drugs: April 2026 Insights
In April 2026, the FDA granted Fast Track Designation to several oncology drugs, signaling significant advancements in cancer treatment. This article explores the implications for pharmaceutical teams and investors.